So many people wait years for a dementia diagnosis—long after symptoms begin. Why? And what can we do about it now?
Trontinemab, an experimental drug developed by Roche, has sparked excitement in large trials for slowing Alzheimer's faster and safer than anything before.
Leqembi, the first Alzheimer's-modifying drug, is a giant step forward—but how many people are getting it, and what does it really cost the average American? We dig into the numbers, the barriers, and the path forward.
Does pain relief risk cognitive cost? A major new study of almost 200,000 people says yes—and the price may be higher than we thought.
Why Do Babies Have More Alzheimer’s Protein Than Adults? A Surprising Clue to Future Treatments
Diagnosing the right dementia type often takes months. It can make a big difference. Mayo Clinic’s AI tool identifies 9 dementia types, including Alzheimer’s, with one scan — a transformative advance in early, accurate diagnosis.
Bill Gates says, "I am blown away by how much we have learned about Alzheimer’s disease over the last couple years." See his compelling video and insight-filled blog post.
Adopting the MIND diet—even later in life—is linked with reduced dementia risk
See one of the largest and most comprehensive studies identifying where dementia occurs most often.
Sleep aid lemborexant (better known by its brand name Dayvigo) showed 40% more hippocampal brain volume than other drugs.
Lecanemab is today's #1 Alzheimer's antibody. (Brand name: Leqembi) Washington University researchers found Lecanemab's adverse events to be rare and manageable in very mild or mild Alzheimer's.
New Test Provides Less Invasive Option, Reduces Reliance on PET Scans and Increases Diagnosis Accessibility
